Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid

Abstract

The results of this study indicate that UDCA therapy is a dominant strategy as it confers reduced morbidity and mortality, as well as cost savings, compared with standard therapy.